Kluwer Patent Blog published a new post by Kirill Osipov July 29, 2025 The patent dispute relating to the cancer drug Tagrisso (osimertinib) and the role of the Federal Antimonopoly Service (FAS) of Russia as the main regulator of the case is the theme of the new post by Kirill Osipov, the Head of Legal Department at ARS-Patent. In cooperation with experts from the leading IP firms worldwide, Kluwer Patent Blog provides updates and developments in patent law, featuring in-depth analysis and insights from leading IP professionals. You can read the post on Kluwer Patent Blog via the link. Make an enquiry
MEET WITH US ARS-Patent will attend the APAA 2025 in Kuala Lumpur2025-10-03We are pleased to announce that ARS-Patent will be a part of the upcoming global IP event APAA 2025, which is the 21st General Assembly and 77th & 78t...Read moreARS-Patent at AIPPI World Congress 2025 in Yokohama2025-08-18The AIPPI World Congress 2025, which will be held in Yokohama, Japan, from September 13-16, will be a significant international gathering for intellec...Read moreSee all Events
ARS-Patent will attend the APAA 2025 in Kuala Lumpur2025-10-03We are pleased to announce that ARS-Patent will be a part of the upcoming global IP event APAA 2025, which is the 21st General Assembly and 77th & 78t...Read more
ARS-Patent at AIPPI World Congress 2025 in Yokohama2025-08-18The AIPPI World Congress 2025, which will be held in Yokohama, Japan, from September 13-16, will be a significant international gathering for intellec...Read more
